Abstract
PSMA-targeted radiopharmaceutical therapy is an established treatment option for metastatic castration-resistant prostate cancer (mCRPC). However, response rates and duration using 177Lu-PSMA-617 vary considerably between patients. Quantitative 177Lu SPECT imaging is one approach that may be leveraged to more closely monitor inter-cycle response, as well as patient-specific absorbed doses. In this work, we describe our experience implementing quantitative imaging throughout the course of 177Lu-PSMA treatment, including serial SPECT imaging to monitor response and for individualized dosimetry. We also describe our imaging protocols and dose calculation workflows for 3D voxelized patient-specific organ and tumor dosimetry, including a review of the current landscape and efforts towards harmonized dosimetry.
Original language | English (US) |
---|---|
Article number | 1291253 |
Journal | Frontiers in Nuclear Medicine |
Volume | 3 |
DOIs | |
State | Published - 2023 |
Keywords
- dosimetry
- lutetium-177
- prostate cancer
- PSMA
- SPECT/CT
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging